20 Jul 2021

Appointment of Fred S. Zeidman to the Board of Directors of Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. (the “Company”), announced today that Mr. Fred S. Zeidman has been appointed to the Boards of Directors and Chairman of Nominating and Corporate Governance Committee of the Company. The Board of Directors ratified and approved, the appointment of Mr. Zeidman to the Board of Directors. The appointment of Mr. Zeidman to the Company’s Board of Directors is effective June 24, 2021. “We...

Read More

14 Dec 2020


Collaboration focused on developing point of care diagnostic test to quantify IL-6 in whole blood. Acton, MA,  Dec 8, 2020 – Bluejay Diagnostics, Inc. (Bluejay, Acton, MA) today announced a collaboration agreement with Toray Industries, Inc. (Toray, Tokyo, Japan) to develop a minimally-invasive, point-of-care test for COVID-19 patients to assess progression of the disease. Symphony™ IL-6 is the first of many products to be developed...

Read More

09 Apr 2019

Bluejay Diagnostics, Inc. Announces CE Mark for its Allereye® Tear Total IgE Test

Acton, MA – April 9, 2019 – Bluejay Diagnostics, Inc. (Bluejay) is pleased to announce that it has  received CE Mark for the Allereye® Tear Total IgE Test. Allereye, an FDA-Cleared point-of-care (POC) device, offers healthcare providers a cost-effective, non-invasive, reliable, easy-to-use solution to aid in the diagnosis of allergic conjunctivitis. Bluejay expects to launch the product in Q2 of 2019 throughout Europe and the Middle...

Read More

01 Apr 2019

Bluejay Diagnostics, Inc. and U.S. Navy Enter Co-Operative Research and Development Agreement to Develop Non-Invasive Point-of-Care Tests for Lyme Disease

Acton, MA – April 1, 2019 – Bluejay Diagnostics, Inc. (Bluejay) is pleased to announce a new Cooperative Research & Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC), Silver Spring, Md. The project, which will take place in Maryland, will investigate and develop a non-invasive point-of-care test for Lyme disease with the goal of improving detection of Lyme disease at an early stage....

Read More

22 May 2017

Bluejay Diagnostics’ Board of Directors Announces Appointment of Douglas C. Wurth as Chairman

Acton, MA – May 22, 2017 – Bluejay Diagnostics, Inc. (Bluejay) today announced that its board of directors unanimously named Douglas C. Wurth as the Company’s chairman, effective immediately. Mr. Wurth recently retired from J.P. Morgan Chase after a successful 19-year career with the Firm, where he was the Chief Executive Officer of Alternative Investments for J.P. Morgan Asset Management. In this role, he led...

Read More

27 Feb 2017

Bluejay Diagnostics, Inc. Announces Clinical Research Collaboration to Development of Care Test for Allergic Conjunctivitis

Collaboration focused on developing non-invasive diagnostic test to identify total IgE in human tears. Acton, MA – February 27, 2017 – Bluejay Diagnostics, Inc. (Bluejay) today announced a collaborative clinical research agreement with Hitachi Chemical Co., Ltd. (Hitachi Chemical) to develop a non-invasive, point-of-care test that measures total IgE in human tears. The technology could be used to aid in the diagnosis of Allergic Conjunctivitis,...

Read More